vidarabine has been researched along with 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giles, FJ; Gojo, I; Greer, J; Johnson, B; Karp, JE; Low, J; Morris, L; Sznol, M; Thein, M | 1 |
| Blackford, AL; Carraway, HE; Gojo, I; Gore, SD; Greer, JM; Ivy, SP; Karp, JE; Levis, MJ; McDevitt, MA; Pratz, KW; Smith, BD; Zeidner, JF | 1 |
2 trial(s) available for vidarabine and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
| Article | Year |
|---|---|
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloprol
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Recurrence; Thiosemicarbazones; Treatment Outcome; Vidarabine | 2008 |
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Outcome; Vidarabine | 2014 |